Personalized medicine in gastric cancer: Where are we and where are we going?

Jácome AA, Coutinho AK, Lima EM, Andrade AC, Dos Santos JS. Abstract Despite improvements in adjuvant therapies for gastric cancer in recent years, the disease is characterized by high recurrence rates and a dismal prognosis. The major improvement in the treatment of recurrent or metastatic gastric cancer in recent years has been the incorporation of(…)

Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients.

Goulielmos GN, Zervou MI, Myrthianou E, Burska A, Niewold TB, Ponchel F. Abstract Rapid advances in genotyping technology, analytical methods, and the establishment of large cohorts for population genetic studies have resulted in a large new body of information about the genetic basis of human rheumatoid arthritis (RA). Improved understanding of the root pathogenesis of(…)

Toward precision medicine of breast cancer.

Carels N, Spinassé LB, Tilli TM, Tuszynski JA. Abstract In this review, we report on breast cancer’s molecular features and on how high throughput technologies are helping in understanding the dynamics of tumorigenesis and cancer progression with the aim of developing precision medicine methods. We first address the current state of the art in breast(…)

Biologic efficacy optimization-a step towards personalized medicine.

Kiely PD Abstract This following is a review of the factors that influence the outcome of biologic agents in the treatment of adult RA and, when synthesized into the clinical decision-making process, enhance optimization. Adiposity can exacerbate inflammatory diseases; patients with high BMI have worse outcomes from RA, including TNF inhibitors (TNFis), whereas the efficacy(…)

Paving the way of systems biology and precision medicine in allergic diseases: The MeDALL success story

BN17, Lodrup-Carlsen K18, Koppelman GH19, Sunyer J4,5,6,7, Zuberbier T20, Annesi-Maesano I21, Arno A22, Bindslev-Jensen C23, De Carlo G24, Forastiere F25, Heinrich J26, Kowalski ML27, Maier D28, Melén E29, Palkonen S24, Smit HA30, Standl M26, Wright J31, Arsanoj A32, Benet M4, Balardini N14,33, Garcia-Aymerich J4,5,6,7, Gehring U34, Guerra S4, Hohman C35, Kull I14,36, Lupinek C13, Pinart(…)

Special Review: Caught in the Crosshairs: Targeted Drugs and Personalized Medicine.

Cancer J. 2015 Nov-Dec;21(6):441-7. doi: 10.1097/PPO.0000000000000161. Ferreira BI1, Hill R, Link W. Abstract All drugs have molecular targets; however, this does not mean that they are targeted therapeutics. Only by the interaction with a disease-specific molecule can the drug be classified as a targeted therapeutic. This is often not clearly defined and might refer to(…)

A novel Alzheimer disease locus located near the gene encoding tau protein.

Mol Psychiatry. 2016 Jan;21(1):108-117. doi: 10.1038/mp.2015.23. Epub 2015 Mar 17. Jun G et a. Abstract APOE ɛ4, the most significant genetic risk factor for Alzheimer disease (AD), may mask effects of other loci. We re-analyzed genome-wide association study (GWAS) data from the International Genomics of Alzheimer‘s Project (IGAP) Consortium in APOE ɛ4+ (10 352 cases and(…)

Schizophrenia’s strongest known genetic risk deconstructed

  Suspect gene may trigger runaway synaptic pruning during adolescence – NIH-funded study January 27, 2016 • Press Release   Versions of a gene linked to schizophrenia may trigger runaway pruning of the teenage brain’s still-maturing communications infrastructure, NIH-funded researchers have discovered.  People with the illness show fewer such connections between neurons, or synapses.  The gene(…)